lorlatinib (Lorviqua) accepted for use within NHSScotland on an interim basis subject to ongoing evaluation and reassessment

The SMC has accepted lorlatinib monotherapy for treatment of anaplastic lymphoma kinase (ALK)-positive advanced NSCLC whose disease has progressed after alectinib or ceritinib as the first ALK tyrosine kinase inhibitor (TKI) therapy, or crizotinib and at least one other ALK TKI.

SPS commentary:

In DRAFT NICE guidance, lorlatinib was not recommended for this indication on the basis that lorlatinib had not been compared directly with other drugs for this indication. Additionally, the methods and results of the cost-effectiveness modelling were considered uncertain because of limitations in the data and how the treatments are compared indirectly.


Scottish Medicines Consortium

Resource links:

Draft NICE guidance (January 2020)